TB-500 UK: Research Reference 2026

TB-500 (Thymosin Beta-4) is a 43-amino-acid peptide that is a synthetic version of the endogenous protein Thymosin Beta-4 (Tβ4). The peptide is found in high concentrations in blood platelets, wound fluid, and regenerating tissues, and has been studied for its role in wound healing, cellular migration, and tissue regeneration.

The peptide is an actin-sequestering protein that regulates the cytoskeleton and influences cell motility, migration, and differentiation. Thymosin Beta-4 is the most abundant member of the beta-thymosin family and is highly conserved across species.

For UK research laboratories, TB-500 serves as a reference compound for studies examining actin dynamics, wound healing, and cellular migration. The peptide is not licensed as a medicine and is supplied for research use only.

TB-500 is a 43-amino-acid peptide with the following structural characteristics:

• Sequence: 43 amino acids (Ac-SDKP sequence with central actin-binding domain)
• Molecular weight: Approximately 4,963 Da
• N-terminus: Acetylated (Ac-SDKP)
• C-terminus: Free carboxyl
• Origin: Synthetic version of endogenous Thymosin Beta-4

The peptide contains an actin-binding domain (residues 17-23) that is critical for its biological activity. The N-terminal SDKP sequence is the same as the anti-fibrotic tetrapeptide, which may contribute to anti-inflammatory effects. The peptide is highly conserved across mammalian species, with >95% sequence identity.

TB-500 operates through several mechanisms in cellular and in vitro models:

Actin Regulation

TB-500 is an actin-sequestering protein that binds to G-actin (monomeric actin) and prevents its polymerisation into F-actin. This regulation of the actin cytoskeleton influences cell motility, migration, and shape. In cellular models, TB-500 promotes lamellipodia formation and directional cell migration, which are critical for wound healing.

Cellular Migration

The peptide enhances cell migration in wound-healing models. In fibroblast and epithelial cell cultures, TB-500 increases the rate of scratch wound closure through enhanced migration and proliferation. The actin-regulating activity is central to this migratory effect, as the cytoskeleton must remodel for cell movement.

Angiogenesis

TB-500 promotes angiogenesis in endothelial cell models. The peptide stimulates endothelial cell migration, tube formation, and vessel sprouting. The mechanism involves upregulation of VEGF and other angiogenic factors, as well as direct effects on endothelial cell motility.

Anti-Inflammatory Effects

The peptide modulates inflammatory responses in cellular models. TB-500 reduces pro-inflammatory cytokine production and promotes anti-inflammatory signalling. The N-terminal SDKP sequence may contribute to anti-fibrotic and anti-inflammatory effects through distinct pathways from the actin-binding domain.

Tissue Regeneration

In regenerative models, TB-500 supports tissue repair through multiple mechanisms: enhanced cell migration, reduced inflammation, increased angiogenesis, and modulation of the extracellular matrix. The peptide's effects on multiple regenerative processes make it relevant for wound healing and tissue repair research.

TB-500 is employed across multiple research domains in UK laboratories:

Wound Healing Research

In vitro studies examine TB-500's effects on wound closure, cellular migration, and tissue regeneration. Researchers use scratch assays, organotypic cultures, and tissue explants to model wound healing and examine the peptide's effects on repair processes.

Musculoskeletal Research

Tendon, ligament, and muscle cell cultures are used to examine TB-500's effects on connective tissue repair. The peptide's actin-regulating activity is relevant for myocyte and fibroblast function in tissue repair models.

Cardiovascular Research

Endothelial and cardiac cell models examine TB-500's effects on angiogenesis, vascular repair, and cardioprotection. The peptide's role in vessel formation and tissue perfusion is relevant for ischemia and vascular injury models.

Ocular Research

Corneal epithelial and endothelial cell models examine TB-500's effects on ocular wound healing. The peptide's promotion of epithelial migration and wound closure is relevant for corneal injury and surgical repair models.

Comparative Regenerative Peptides

TB-500 is compared to BPC-157 and other regenerative peptides in cellular studies. Research questions examine whether different mechanisms (actin regulation vs. angiogenic signalling) produce complementary effects in tissue repair.

UK research laboratories employ several standard cellular models for TB-500 studies:

Fibroblast Scratch Assays

Primary fibroblasts and fibroblast cell lines are used in scratch wound assays to measure migration and proliferation. Endpoints include wound closure rate, actin cytoskeleton organisation, and lamellipodia formation. Time-lapse microscopy is used to track cell migration dynamics.

Endothelial Tube Formation

HUVEC and other endothelial cell lines are used in Matrigel tube formation assays to examine angiogenic effects. Endpoints include tube length, branch points, and network complexity. VEGF and NO production are measured in parallel.

Epithelial Wound Healing

Corneal epithelial cells and skin keratinocytes are used in scratch assays to examine wound closure. The peptide's effects on epithelial migration, proliferation, and differentiation are examined in organotypic cultures.

Myocyte Studies

Primary cardiomyocytes and skeletal muscle cells are used to examine TB-500's effects on cell survival, migration, and regeneration. Endpoints include cell viability under stress, metabolic activity, and cytoskeletal organisation.

Actin Cytoskeleton

Fluorescent phalloidin staining is used to examine F-actin organisation in response to TB-500. Cell shape, stress fibre formation, and lamellipodia dynamics are quantified in fibroblast and endothelial cells.

TB-500's safety profile is based on preclinical cellular and animal studies. In vitro toxicology screens have not identified significant cytotoxicity at research-relevant concentrations.

In animal studies, the peptide has been well tolerated at standard research doses. The endogenous nature of Thymosin Beta-4 suggests low inherent toxicity, as the peptide is naturally present in human tissues and blood. No organ-specific toxicity has been reported at standard doses.

The peptide's effects on cell migration raise theoretical considerations about promoting migration in non-target cells, though this has not been observed as a specific safety concern in preclinical studies.

Standard laboratory precautions apply: TB-500 is a research peptide, not a medicine or dietary supplement. It is supplied for in vitro and laboratory animal research only.

TB-500 is supplied as a lyophilised powder in research-grade vials. Standard laboratory preparation:

• Reconstitution: Bacteriostatic water (0.9% benzyl alcohol) is recommended for laboratory preparations
• Concentration: Typical research stock concentrations range from 1–10 mg/mL depending on assay requirements
• Storage: Lyophilised powder at −20 °C; reconstituted solution at 2–8 °C, protected from light
• Stability: Reconstituted solutions are stable for 7–14 days under refrigeration; for extended studies, aliquot and freeze at −20 °C
• Solubility: The peptide is generally soluble in aqueous solutions; brief vortexing may aid dissolution
• Actin binding: The peptide binds to G-actin; researchers should account for this in cellular assays measuring actin dynamics

The peptide's stability and solubility are generally favourable, though standard peptide handling precautions apply.

TB-500 is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA.

For UK research laboratories, TB-500 is available as a research-grade reference material. Sourcing should include:

• Certificate of Analysis confirming ≥98% purity (HPLC)
• Mass spectrometry identity confirmation (molecular weight ~4,963 Da)
• Batch-specific testing documentation
• Appropriate storage and shipping conditions (cold chain)
• Research-use-only labelling

Researchers should ensure compliance with institutional ethics approvals for animal studies, and adhere to standard laboratory safety protocols for peptide handling.